Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer

Lung Cancer

Volumn 78, Issue 3, 2012, Pages 253-258

  Connolly, G C ^a   Dalal, M ^b   Lin, J ^c   Khorana, A A ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

^b SANOFI   (France)

^c Novosys Health   (United States)

Author keywords

Cancer associated thrombosis; Cost of care; Health resource utilization; Lung cancer; Pulmonary embolism; Venous thromboembolism

Indexed keywords

ANTIANEMIC AGENT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOXORUBICIN; OXALIPLATIN;

ADULT; AGED; ARTICLE; BILLING AND CLAIMS; BLEEDING; CANCER CHEMOTHERAPY; CHARLSON COMORBIDITY INDEX; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH CARE COST; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AMBULATORY CARE; CASE-CONTROL STUDIES; COMORBIDITY; FEMALE; HEALTH EXPENDITURES; HOSPITALIZATION; HUMANS; HYPERTENSION; INCIDENCE; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84868303846     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.09.007     Document Type: Article

References (38)

1. Heit J.A., O'Fallon W.M., Petterson T.M., Lohse C.M., Silverstein M.D., Mohr D.N., et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002, 162:1245-1248.
2. Blom J.W., Vanderschoot J.P., Oostindier M.J., Osanto S., van der Meer F.J., Rosendaal F.R. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006, 4:529-535.
3. Khorana A.A., Francis C.W., Culakova E., Fisher R.I., Kuderer N.M., Lyman G.H. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006, 24:484-490.
4. Stein P.D., Beemath A., Meyers F.A., Skaf E., Sanchez J., Olson R.E. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006, 119:60-68.
5. Levitan N., Dowlati A., Remick S.C., Tahsildar H.I., Sivinski L.D., Beyth R., et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999, 78:285-291.
6. Chew H.K., Wun T., Harvey D., Zhou H., White R.H. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006, 166:458-464.
7. Khorana A.A., Francis C.W., Culakova E., Kuderer N.M., Lyman G.H. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007, 110:2339-2346.
8. Tagalakis V., Levi D., Agulnik J.S., Cohen V., Kasymjanova G., Small D. High risk of deep vein thrombosis in patients with non-small cell lung cancer: a cohort study of 493 patients. J Thorac Oncol 2007, 2:729-734.
9. Numico G., Garrone O., Dongiovanni V., Silvestris N., Colantonio I., Di Costanzo G., et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 2005, 103:994-999.
10. de Meis E., Pinheiro V.R., Zamboni M.M., Guedes M.T., Castilho I.A., Martinez M.M., et al. Clotting, immune system, and venous thrombosis in lung adenocarcinoma patients: a prospective study. Cancer Invest 2009, 27:989-997.
11. Trujillo-Santos J., Nieto J.A., Tiberio G., Piccioli A., Di Micco P., Prandoni P., et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008, 100:435-439.
12. Prandoni P., Lensing A.W., Piccioli A., Bernardi E., Simioni P., Girolami B., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002, 100:3484-3488.
13. Kalweit G., Huwer H., Volkmer I., Petzold T., Gams E. Pulmonary embolism: a frequent cause of acute fatality after lung resection. Eur J Cardiothorac Surg 1996, 10:242-246. [discussion 246-7].
14. Chuang Y.M., Yu C.J. Clinical characteristics and outcomes of lung cancer with pulmonary embolism. Oncology 2009, 77:100-106.
15. Mason D.P., Quader M.A., Blackstone E.H., Rajeswaran J., DeCamp M.M., Murthy S.C., et al. Thromboembolism after pneumonectomy for malignancy: an independent marker of poor outcome. J Thorac Cardiovasc Surg 2006, 131:711-718.
16. Hicks L.K., Cheung M.C., Ding K., Hasan B., Seymour L., Le Maitre A., et al. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Cancer 2009, 115:5516-5525.
17. Lang K., Marciniak M.D., Faries D., Stokes M., Buesching D., Earle C., et al. Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States. Lung Cancer 2009, 63:264-270.
18. Wang J., Kuo Y.F., Freeman J., Markowitz A.B., Goodwin J.S. Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer. Cancer 2008, 112:382-390.
19. Starling N., Rao S., Cunningham D., Iveson T., Nicolson M., Coxon F., et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 2009, 27(23):3786-3793.
20. Rajeswaran A., Trojan A., Burnand B., Giannelli M. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 2008, 59:1-11.
21. Azzoli C.G., Baker S., Temin S., Pao W., Aliff T., Brahmer J., et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
22. Scappaticci F.A., Skillings J.R., Holden S.N., Gerber H.P., Miller K., Kabbinavar F., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007, 99:1232-1239.
23. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
24. Cao Y., Tan A., Gao F., Liu L., Liao C., Mo Z. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis 2009, 24:677-685.
25. Kroger K., Weiland D., Ose C., Neumann N., Weiss S., Hirsch C., et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006, 17:297-303.
26. Chew H.K., Davies A.M., Wun T., Harvey D., Zhou H., White R.H. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 2008, 6:601-608.
27. Agnelli G., George D.J., Fisher W., Kakkar A.K., Lassen M.R., Mismetti P., et al. The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. J Clin Oncol 2011, 29:LBA9014.
28. Agnelli G., Gussoni G., Bianchini C., Verso M., Mandala M., Cavanna L., et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009, 10:943-949.
29. Blom J.W., Osanto S., Rosendaal F.R. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost 2004, 2:1760-1765.
30. Zecchina G., Ghio P., Bosio S., Cravino M., Camaschella C., Scagliotti G.V. Reactive thrombocytosis might contribute to chemotherapy-related thrombophilia in patients with lung cancer. Clin Lung Cancer 2007, 8:264-267.
31. Gabazza E.C., Taguchi O., Yamakami T., Machishi M., Ibata H., Suzuki S. Evaluating prethrombotic state in lung cancer using molecular markers. Chest 1993, 103:196-200.
32. Sawada M., Miyake S., Ohdama S., Matsubara O., Masuda S., Yakumaru K., et al. Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. Br J Cancer 1999, 79:472-477.
33. Uzun O., Atasoy Y., Findik S., Atici A.G., Erkan L. A prospective evaluation of hemoptysis cases in a tertiary referral hospital. Clin Respir J 2010, 4:131-138.
34. Hapani S., Sher A., Chu D., Wu S. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 2010, 79:27-38.
35. Alikhan R., Cohen A.T., Combe S., Samama M.M., Desjardins L., Eldor A., et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003, 14:341-346.
36. Samama M.M., Cohen A.T., Darmon J.Y., Desjardins L., Eldor A., Janbon C., et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999, 341:793-800.
37. Cohen A.T., Davidson B.L., Gallus A.S., Lassen M.R., Prins M.H., Tomkowski W., et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006, 332:325-329.
38. Leizorovicz A., Cohen A.T., Turpie A.G., Olsson C.G., Vaitkus P.T., Goldhaber S.Z. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004, 110:874-879.